Key result
Combined NLR and left atrial reservoir strain predict subclinical CTRCD with an AUC of 0.90.
Why the study?
Anthracycline cardiotoxicity may involve systemic inflammation, but the predictive value of combining neutrophil-to-lymphocyte ratio with left atrial reservoir longitudinal strain for subclinical cancer therapy-related cardiac dysfunction was unknown.
Does the combination of T2 neutrophil-to-lymphocyte ratio and relative decrease in left atrial reservoir longitudinal strain predict subclinical cancer therapy-related cardiac dysfunction in breast cancer patients undergoing anthracycline chemotherapy?
Observational (n=85)
No
Does the combination of T2 neutrophil-to-lymphocyte ratio and relative decrease in left atrial reservoir longitudinal strain predict subclinical cancer therapy-related cardiac dysfunction in breast cancer patients undergoing anthracycline chemotherapy?
Combining the neutrophil-to-lymphocyte ratio after the second chemotherapy cycle with the relative decrease in left atrial reservoir longitudinal strain provides a highly accurate early prediction model for subclinical anthracycline-induced cardiotoxicity in breast cancer patients.
May support early risk stratification in anthracycline-treated breast cancer; hypothesis-generating pending prospective validation.
Objective Anthracycline-related cardiotoxicity may involve systemic inflammatory responses, and the neutrophil-to-lymphocyte ratio may change during chemotherapy as a marker for inflammatory and immune status. Considering this, we designed the present study to assess the predictive value of neutrophil-to-lymphocyte ratio combined with left atrial reservoir longitudinal strain for subclinical cancer therapy–related cardiac dysfunction during anthracycline chemotherapy in patients with breast cancer. Methods This prospective observational study enrolled 85 patients with breast cancer undergoing anthracycline chemotherapy. Neutrophil-to-lymphocyte ratio and left atrial reservoir longitudinal strain were measured before chemotherapy (T0), after the second cycle (T2), and after the fourth cycle (T4). Subclinical cancer therapy–related cardiac dysfunction was defined as a normal left ventricular ejection fraction with a ≥15% decrease in left ventricular global longitudinal strain compared with that at baseline. The predictive efficacy of the relative decrease in left atrial reservoir longitudinal strain, T2 neutrophil-to-lymphocyte ratio, and their combined model for subclinical cancer therapy–related cardiac dysfunction at T4 was evaluated using receiver operating characteristic curves. Results We found that 29.41% of the patients developed subclinical cancer therapy–related cardiac dysfunction. Multivariate analysis showed that both T2 neutrophil-to-lymphocyte ratio (odds ratio = 1.611, p = 0.002) and relative decrease in left atrial reservoir longitudinal strain (odds ratio = 1.426, p < 0.001) were independent predictors. Receiver operating characteristic analysis revealed an area under the curve of 0.896 for the combined model. Conclusions This study provides preliminary evidence for an association of T2 neutrophil-to-lymphocyte ratio and relative decrease in left atrial reservoir longitudinal strain with subclinical cancer therapy–related cardiac dysfunction during anthracycline chemotherapy in patients with breast cancer. In this cohort, their combined use suggested good predictive value.
No takes yet. Share an insight, caveat, or question.
Shao et al. (2026) conducted an observational in Breast cancer (n=85). T2 neutrophil-to-lymphocyte ratio (NLR) was evaluated on Subclinical cancer therapy-related cardiac dysfunction (CTRCD) (OR 1.611, 95% CI 1.193-2.179, p=0.002). The combined model of T2 neutrophil-to-lymphocyte ratio and relative decrease in left atrial reservoir longitudinal strain strongly predicted subclinical cancer therapy-related cardiac dysfunction with an AUC of 0.896.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: